UBS Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $288
Alnylam Pharmaceuticals, Inc +0.72% Pre
Alnylam Pharmaceuticals, Inc ALNY | 286.91 286.91 | +0.72% 0.00% Pre |
UBS analyst Eliana Merle maintains Alnylam Pharmaceuticals (NASDAQ:
ALNY) with a Buy and raises the price target from $253 to $288.